CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Acalabrutinib, a Selective and Irreversible Bruton's Tyrosine Kinase Inhibitor, in Japanese Adult Patients With Advanced B-cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03198650
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:11.896324+00:00
Published At: 2025-10-09T00:00:00+00:00
Record Updated At: 2025-10-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Part1: Advanced B-cell Malignancies", "Part2: r/rCLL and r/rMCL", "Part3: Untreated CLL"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-09"
protocolSection.identificationModule.nctId: "NCT03198650"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Acalabrutinib, a Selective and Irreversible Bruton\u0027s Tyrosine Kinase Inhibitor, in Japanese Adult Patients With Advanced B-cell Malignancies"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.